Pharming « Terug naar discussie overzicht

quote:

Bio NL schreef op 31 augustus 2018 13:20:

Lucht flessen Vol ??
Zwembroek dan wel bikini aan?

Het Duiken gaat een aanvang nemen.
Hold the air inn

quote:

Up-Up-Up schreef op 31 augustus 2018 14:39:

Wat een verschrikkelijk laag volume! Zo kunnen de shorters niet coveren natuurlijk, tijd voor een stijging.

quote:

Bio NL schreef op 31 augustus 2018 13:20:

Lucht flessen Vol ??
Zwembroek dan wel bikini aan?

Het Duiken gaat een aanvang nemen.
Hold the air innLucht flessen Vol ??

quote:

beeldscherm schreef op 31 augustus 2018 14:44:

reden waarom alles misschien iets langer duurt,Basel, zou kunnen zijn,

Depending on the results of the Basel study, follow-up clinical development could be initiated
? If the primary marker gives a positive signal, there could be clear therapeutic utility to
offset risk of renal damage for at-risk patients
? A formal Phase II study in CIN could be developed and initiated

dat ze al positieve resultaten hebben,bijna 2mnd geleden, maar dat ze al in gesprek zijn met een evt parten om dit verder te ontwikkelen, want alles zelf doen is m.i een onmogelijke opgave ($) dus misschien gaan ze de markt verrassen,mocht dit zo zijn dan schiet dit aandeel als een raket omhoog ... !!!

quote:

Peter Markus schreef op 31 augustus 2018 13:20:

[...]Theoretisch had je ze al 5 keer kunnen verkopen boven de € 1.45 en onder de € 1.30 kunnen terugkopen.
Achteraf jammer dat ik dat niet gedaan heb.
Zou een hoog rendement hebben gegeven.
PM

quote:

Jan70 de kleine belegger schreef op 31 augustus 2018 12:25:

[...]nou...
Iedereen is overtuigd dat profylactisch gebruik word goed gekeurd.
Iedereen verwacht goed nieuws uit "Basel".
Wordt altijd aangegeven dat "de markt" ongeveer 9 maanden voor loopt.
Ook ik ben van mening dat het goede nieuws nog niet is ingeprijsd. Vraag ik me wel af: waarom is het nog niet ingeprijsd?
Waarom zijn er zo weinig kopers in de markt. Zelf zou ik meer over hebben voor een aandeel dan de huidige koers (al zit ik natuurlijk ook liever voor een dubbeltje op de eerste rij), maar blijkbaar denken anderen daar anders over (waarom?).
Niet beginnen over shorters... als er genoeg kopers zijn / vraag is hebben die shorters het zweet op hun voorhoofd staan en zouden ze het niet in hun hoofd halen om op Pharming short te gaan. Waarom durven zij te shorten?
Waariom is het sentiment zo negatief, terwijl iedreen alleen maar mooie vooruitzichten ziet.

Je vindt het te gek om te antwoorden, jammer. Ik ben ook positief maar vraag me serieus af waarom ik de enigen lijk (als ik de koersontwikkeling zo bekijk).
Zie ik het verkeerd?
Jammer dat het antwoord voor jouw zo duidelijk is, maar je het niet kwijt wilt.

quote:

Investor68 schreef op 31 augustus 2018 14:58:

[...]
I think that there are not so many buyers because the movement of Pharming’s stock price has been discouraging since the past weeks. Pharming stock price seems to be under some kind of control/manipulation. Since the past three weeks, the stock price has been kept under €1,30 per share. Whenever it rises to around €1,293 per share, it is pushed back down to under €1,28 or lower. A continuous downward movement in stock price does not attract buyers. Would you buy a stock if you know very well that the price will fall after you buy it? Most people will buy stocks if they believe that the stocks will rise in value after buying it. Progressive upward movement in stock price attracts buyers. Unfortunately, Pharming stock price has not been allowed to take off since the last three or four weeks and this is discouraging to potential buyers. Pharming stock price is constrained probably by the activities of shorters. There is a few of them in Pharming. When one is leaving, another is coming. Shorters do not like to lose. They always want to win even in situations where a company has presented a very good financial result/updates and this is where stock manipulation comes in. In such situation, instead of allowing the stock price to shoot up, shorters will still push the stock price down by carrying out more sell orders only to buy the stocks back later at a lower price. To use myself as an example, I personally own shares of Pharming and I have been increasing my shares recently. But I have now decided to stop buying more shares because the price keep going down every day. What you think is the lowest price today will become the highest price tomorrow. This situation does not encourage potential buyers. So, I just keep what I have without adding to it.

The presence of Shorters in Pharming has a chilling effect on potential buyers. The result is a depressed stock price that we see now in Pharming—and not only in Pharming but also in many other companies. There are many companies with good financial results. But their stock prices have been kept down by the manipulative activities of shorters. Financial authorities such as the AFM must monitor the activities of shorters more strictly to prevent abuses in the system. This will help to ensure fair competition in the stock market.

quote:

Investor68 schreef op 31 augustus 2018 14:58:

[...]
I think that there are not so many buyers because the movement of Pharming’s stock price has been discouraging since the past weeks. Pharming stock price seems to be under some kind of control/manipulation. Since the past three weeks, the stock price has been kept under €1,30 per share. Whenever it rises to around €1,293 per share, it is pushed back down to under €1,28 or lower. A continuous downward movement in stock price does not attract buyers. Would you buy a stock if you know very well that the price will fall after you buy it? Most people will buy stocks if they believe that the stocks will rise in value after buying it. Progressive upward movement in stock price attracts buyers. Unfortunately, Pharming stock price has not been allowed to take off since the last three or four weeks and this is discouraging to potential buyers. Pharming stock price is constrained probably by the activities of shorters. There is a few of them in Pharming. When one is leaving, another is coming. Shorters do not like to lose. They always want to win even in situations where a company has presented a very good financial result/updates and this is where stock manipulation comes in. In such situation, instead of allowing the stock price to shoot up, shorters will still push the stock price down by carrying out more sell orders only to buy the stocks back later at a lower price. To use myself as an example, I personally own shares of Pharming and I have been increasing my shares recently. But I have now decided to stop buying more shares because the price keep going down every day. What you think is the lowest price today will become the highest price tomorrow. This situation does not encourage potential buyers. So, I just keep what I have without adding to it.

The presence of Shorters in Pharming has a chilling effect on potential buyers. The result is a depressed stock price that we see now in Pharming—and not only in Pharming but also in many other companies. There are many companies with good financial results. But their stock prices have been kept down by the manipulative activities of shorters. Financial authorities such as the AFM must monitor the activities of shorters more strictly to prevent abuses in the system. This will help to ensure fair competition in the stock market.

quote:

Investor68 schreef op 31 augustus 2018 14:58:

....

quote:

monitor schreef op 31 augustus 2018 14:54:

[...]

Dat zei ik voor de cijfers, maar toen werden er een paar geïrriteerd of wilde me niet geloven

quote:

Investor68 schreef op 31 augustus 2018 14:58:

[...]
I think that there are not so many buyers because the movement of Pharming’s stock price has been discouraging since the past weeks. Pharming stock price seems to be under some kind of control/manipulation. Since the past three weeks, the stock price has been kept under €1,30 per share. Whenever it rises to around €1,293 per share, it is pushed back down to under €1,28 or lower. A continuous downward movement in stock price does not attract buyers. Would you buy a stock if you know very well that the price will fall after you buy it? Most people will buy stocks if they believe that the stocks will rise in value after buying it. Progressive upward movement in stock price attracts buyers. Unfortunately, Pharming stock price has not been allowed to take off since the last three or four weeks and this is discouraging to potential buyers. Pharming stock price is constrained probably by the activities of shorters. There is a few of them in Pharming. When one is leaving, another is coming. Shorters do not like to lose. They always want to win even in situations where a company has presented a very good financial result/updates and this is where stock manipulation comes in. In such situation, instead of allowing the stock price to shoot up, shorters will still push the stock price down by carrying out more sell orders only to buy the stocks back later at a lower price. To use myself as an example, I personally own shares of Pharming and I have been increasing my shares recently. But I have now decided to stop buying more shares because the price keep going down every day. What you think is the lowest price today will become the highest price tomorrow. This situation does not encourage potential buyers. So, I just keep what I have without adding to it.

The presence of Shorters in Pharming has a chilling effect on potential buyers. The result is a depressed stock price that we see now in Pharming—and not only in Pharming but also in many other companies. There are many companies with good financial results. But their stock prices have been kept down by the manipulative activities of shorters. Financial authorities such as the AFM must monitor the activities of shorters more strictly to prevent abuses in the system. This will help to ensure fair competition in the stock market.

quote:

Investor68 schreef op 31 augustus 2018 14:58:

[...]
I think that there are not so many buyers .....

quote:

monitor schreef op 31 augustus 2018 14:54:

[...]

Dat zei ik voor de cijfers, maar toen werden er een paar geïrriteerd of wilde me niet geloven

quote:

beeldscherm schreef op 31 augustus 2018 14:44:

reden waarom alles misschien iets langer duurt,Basel, zou kunnen zijn,

Depending on the results of the Basel study, follow-up clinical development could be initiated
? If the primary marker gives a positive signal, there could be clear therapeutic utility to
offset risk of renal damage for at-risk patients
? A formal Phase II study in CIN could be developed and initiated

dat ze al positieve resultaten hebben,bijna 2mnd geleden, maar dat ze al in gesprek zijn met een evt partner om dit verder te ontwikkelen, want alles zelf doen is m.i een onmogelijke opgave ($) dus misschien gaan ze de markt verrassen,mocht dit zo zijn dan schiet dit aandeel als een raket omhoog ... !!!

quote:

beeldscherm schreef op 31 augustus 2018 14:45:

[...]

pharmings prio is natuurlijk Pompe/Fabry